SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak?

Lucidarme, J; Lekshmi, A; Parikh, SR; Bray, JE; Hill, DM; Bratcher, HB; Gray, SJ; Carr, AD; Jolley, KA; Findlow, J; et al. Lucidarme, J; Lekshmi, A; Parikh, SR; Bray, JE; Hill, DM; Bratcher, HB; Gray, SJ; Carr, AD; Jolley, KA; Findlow, J; Campbell, H; Ladhani, SN; Ramsay, ME; Maiden, MCJ; Borrow, R (2017) Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak? J Infect, 75 (2). pp. 95-103. ISSN 1532-2742 https://doi.org/10.1016/j.jinf.2017.05.015
SGUL Authors: Ladhani, Shamez Nizarali

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview

Abstract

The meningococcal ST-11 complex (cc11) causes large invasive disease outbreaks with high case fatality rates, such as serogroup C (MenC) epidemics in industrialised nations in the 1990s and the serogroup W epidemic currently expanding globally. Glycoconjugate vaccines are available for serogroups A, C, W and Y. Broad coverage protein-based vaccines have recently been licensed against serogroup B meningococci (MenB), however, these do not afford universal MenB protection. Capsular switching from MenC to MenB among cc11 organisms is concerning because a large MenB cc11 (B:cc11) outbreak has the potential to cause significant morbidity and mortality. This study aimed to assess the potential for licensed and developmental non-capsular meningococcal vaccines to protect against B:cc11. The population structure and vaccine antigen distribution was determined for a panel of >800 geo-temporally diverse, predominantly MenC cc11 and B:cc11 genomes. The two licensed vaccines potentially protect against many but not all B:cc11 meningococci. Furthermore, strain coverage by these vaccines is often due to a single vaccine antigen and both vaccines are highly susceptible to vaccine escape owing to the apparent dispensability of key proteins used as vaccine antigens. cc11 strains with MenB and MenC capsules warrant special consideration when formulating future non-capsular meningococcal vaccines.

Item Type: Article
Additional Information: Crown Copyright © 2017 Published by Elsevier Ltd on behalf of The British Infection Association. This is an open access article under the Open Government License (OGL) (http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/).
Keywords: Meningococcal, Neisseria meningitidis, ST-11 complex, Serogroup B, Vaccine, Microbiology, 1103 Clinical Sciences
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: J Infect
ISSN: 1532-2742
Language: eng
Dates:
DateEvent
August 2017Published
1 June 2017Published Online
27 May 2017Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Projects:
Project IDFunderFunder ID
087622Wellcome Trusthttp://dx.doi.org/10.13039/100004440
PubMed ID: 28579305
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/109030
Publisher's version: https://doi.org/10.1016/j.jinf.2017.05.015

Actions (login required)

Edit Item Edit Item